| pubmed-article:8520877 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8520877 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:8520877 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:8520877 | lifeskim:mentions | umls-concept:C0011777 | lld:lifeskim |
| pubmed-article:8520877 | lifeskim:mentions | umls-concept:C0061863 | lld:lifeskim |
| pubmed-article:8520877 | lifeskim:mentions | umls-concept:C0332161 | lld:lifeskim |
| pubmed-article:8520877 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8520877 | pubmed:dateCreated | 1996-1-25 | lld:pubmed |
| pubmed-article:8520877 | pubmed:abstractText | The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis. This randomised, double-blind, multicentre, three-arm study was conducted at 21 medical centres. A group of 292 nausea- and emesis-free patients with cancer, who had never had chemotherapy and were scheduled to receive at least 50 mg/m2 cisplatin, were given 3 mg granisetron i.v. in a 15-min infusion with or without 10 mg dexamethasone i.v. completed 5 min prior to high-dose cisplatin and 1 mg granisetron p.o. at +6 h and +12 h. Primary study end-points were control of emesis and nausea. Patients completed a self-report diary every 6 h for the first 24 h. At the end of the 24-h period, the patients who received dexamethasone had a significantly higher complete protection rate from emesis (64% compared to 39%) than those who received no steroid. Similarly, the dexamethasone-treated group had a significantly higher complete plus partial (0-2 emetic episodes) protection rate (84% compared to 64%). This study shows that dexamethasone markedly enhances the antiemetic efficacy of granisetron for acute-onset emesis in high-dose cisplatin chemotherapy. | lld:pubmed |
| pubmed-article:8520877 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8520877 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8520877 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8520877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8520877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8520877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8520877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8520877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8520877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8520877 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8520877 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8520877 | pubmed:issn | 0941-4355 | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:StewartDD | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:ShepherdFF | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:WarrDD | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:RusthovenJJ | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:LatreilleJJ | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:YelleLL | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:HoskinsPP | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:LabergeFF | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:WaldeDD | lld:pubmed |
| pubmed-article:8520877 | pubmed:author | pubmed-author:McMurtrieEE | lld:pubmed |
| pubmed-article:8520877 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8520877 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:8520877 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8520877 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8520877 | pubmed:pagination | 307-12 | lld:pubmed |
| pubmed-article:8520877 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:meshHeading | pubmed-meshheading:8520877-... | lld:pubmed |
| pubmed-article:8520877 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8520877 | pubmed:articleTitle | Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. | lld:pubmed |
| pubmed-article:8520877 | pubmed:affiliation | Hematology-Oncology Division, Hôtel-Dieu de Montréal, Québec, Canada. | lld:pubmed |
| pubmed-article:8520877 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8520877 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8520877 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8520877 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:8520877 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8520877 | lld:pubmed |
